Corcept Therapeutics (CORT) EBT Margin (2012 - 2026)

Corcept Therapeutics has disclosed EBT Margin across 15 years of filings, most recently posting 27.12% for Q1 2026.

• EBT Margin for Q1 2026 came in at 27.12%, down 3323.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.58% (down 1828.0% YoY), and the FY2025 annual result was 8.73%, down 1519.0% from the prior year.
• EBT Margin came in at 27.12% for Q1 2026 at Corcept Therapeutics, down from 4.9% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 32.44% in Q3 2022 to a low of 27.12% in Q1 2026.
• The 5-year median for EBT Margin is 23.84% (2024), against an average of 18.89%.
• Across the five-year window, EBT Margin surged 639 bps in 2024 and plunged 3323 bps in 2026, its largest moves.
• Corcept Therapeutics' EBT Margin stood at 23.56% in 2022, then grew by 15 bps to 27.18% in 2023, then tumbled by 35 bps to 17.57% in 2024, then sank by 72 bps to 4.9% in 2025, then plunged by 653 bps to 27.12% in 2026.
• The last three EBT Margin figures came in at 27.12% (Q1 2026), 4.9% (Q4 2025), and 7.34% (Q3 2025), per Business Quant data.